Oxford Biomedica Plc Stock Total Asset
| OXBDF Stock | USD 2.72 0.10 3.82% |
Oxford Biomedica plc fundamentals help investors to digest information that contributes to Oxford Biomedica's financial success or failures. It also enables traders to predict the movement of Oxford Pink Sheet. The fundamental analysis module provides a way to measure Oxford Biomedica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oxford Biomedica pink sheet.
Oxford |
Oxford Biomedica plc Company Total Asset Analysis
Oxford Biomedica's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Oxford Biomedica Total Asset | 237.23 M |
Most of Oxford Biomedica's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oxford Biomedica plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Oxford Biomedica plc has a Total Asset of 237.23 M. This is 96.85% lower than that of the Healthcare sector and 87.99% lower than that of the Biotechnology industry. The total asset for all United States stocks is 99.19% higher than that of the company.
Oxford Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oxford Biomedica's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oxford Biomedica could also be used in its relative valuation, which is a method of valuing Oxford Biomedica by comparing valuation metrics of similar companies.Oxford Biomedica is currently under evaluation in total asset category among related companies.
Oxford Fundamentals
| Return On Equity | -0.14 | |||
| Return On Asset | -0.024 | |||
| Profit Margin | (0.20) % | |||
| Operating Margin | (0.10) % | |||
| Current Valuation | 436.12 M | |||
| Shares Outstanding | 96.27 M | |||
| Shares Owned By Insiders | 6.19 % | |||
| Shares Owned By Institutions | 62.89 % | |||
| Price To Earning | 17.67 X | |||
| Price To Book | 1.69 X | |||
| Price To Sales | 3.60 X | |||
| Revenue | 142.8 M | |||
| Gross Profit | 82.64 M | |||
| EBITDA | 33.22 M | |||
| Net Income | 19.01 M | |||
| Cash And Equivalents | 118.55 M | |||
| Cash Per Share | 1.23 X | |||
| Total Debt | 107.5 M | |||
| Debt To Equity | 0.41 % | |||
| Current Ratio | 1.83 X | |||
| Book Value Per Share | 2.31 X | |||
| Cash Flow From Operations | 25.45 M | |||
| Earnings Per Share | 0.24 X | |||
| Number Of Employees | 959 | |||
| Beta | 0.97 | |||
| Market Capitalization | 548.76 M | |||
| Total Asset | 237.23 M | |||
| Working Capital | 12.54 M | |||
| Current Asset | 25.71 M | |||
| Current Liabilities | 13.17 M | |||
| Z Score | 3.0 | |||
| Net Asset | 237.23 M |
About Oxford Biomedica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oxford Biomedica plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oxford Biomedica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oxford Biomedica plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oxford Biomedica plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Oxford Biomedica plc information on this page should be used as a complementary analysis to other Oxford Biomedica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Oxford Pink Sheet analysis
When running Oxford Biomedica's price analysis, check to measure Oxford Biomedica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oxford Biomedica is operating at the current time. Most of Oxford Biomedica's value examination focuses on studying past and present price action to predict the probability of Oxford Biomedica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oxford Biomedica's price. Additionally, you may evaluate how the addition of Oxford Biomedica to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |